Celldex Therapeutics, Inc. (CLDX)

NASDAQ

$27.08

-$0.43 (1.56%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$26.82$27.90

Open $27.90

52 Week Range

$14.40$30.50

Previous Close $27.51

Market Cap1.80B

Volume670.89K

Avg Volume924.06K

P/E (TTM)-9.01

EPS (TTM)$-3.01

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Celldex Therapeutics, Inc.

DEC92025

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Source: GlobeNewsWire•6 days ago

HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticar...

NOV102025

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Source: GlobeNewsWire•35 days ago

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of stra...

NOV72025

Celldex to Present at Upcoming Investor Conferences

Source: GlobeNewsWire•38 days ago

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:...

SEP172025

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Source: GlobeNewsWire•90 days ago

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU...